Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Operations: 2013-2025

Historic Cash from Operations for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$46.3 million.

  • Coherus Oncology's Cash from Operations rose 25.28% to -$46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.2 million, marking a year-over-year decrease of 45.50%. This contributed to the annual value of -$20.4 million for FY2024, which is 88.31% up from last year.
  • Per Coherus Oncology's latest filing, its Cash from Operations stood at -$46.3 million for Q3 2025, which was up 0.63% from -$46.6 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Cash from Operations ranged from a high of $59.7 million in Q2 2024 and a low of -$100.0 million during Q4 2022.
  • Its 3-year average for Cash from Operations is -$28.6 million, with a median of -$46.3 million in 2025.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 26,515.43% in 2022, then spiked by 321.13% in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Cash from Operations stood at -$52.3 million in 2021, then tumbled by 91.03% to -$100.0 million in 2022, then soared by 87.06% to -$12.9 million in 2023, then surged by 321.13% to $28.6 million in 2024, then grew by 25.28% to -$46.3 million in 2025.
  • Its Cash from Operations stands at -$46.3 million for Q3 2025, versus -$46.6 million for Q2 2025 and -$25.8 million for Q1 2025.